Three Fellows in the Department of Pathology and the Center for Cardiovascular Diseases and Sciences have been awarded Fellowships funding their ongoing research into cardiovascular diseases.
Welcome to the Department of Pathology at LSU Health Shreveport. As having responsibilities in both basic science and clinical medicine, our department serves as a bridge between the two. Our department has 24 faculty members, 12 residents, three fellows and approximately 200 administrative staff and laboratory workers, including post-docs, research assistants, medical technologists, technicians, and Pathologists' Assistants. For more than 50 years, this department has trained and educated researchers and healthcare professionals who have excelled nationally and internationally in academics, industry, and in the private community setting. We are located in northwest Louisiana in a city that has a vast array of cultural and recreational offerings, good schools, several colleges, and a low cost of living.
The department has a number of world class researchers. Our Research Division brings in over $4.3 million from the NIH and other funding agencies placing our department in the top 75th percentile in the United States. They participate in both basic research, translational research, and clinical trials. They have also been active in the COVID-19 pandemic, participating in the creation of the Emerging Viral Threat (EVT) Laboratory, making LSU Health Shreveport one of the first medical school labs to institute COVID-19 testing in this region. The department’s research leadership was also vital in establishing our Center of Excellence for Cardiovascular Diseases and Science (CCDS) and the NIH-funded Center of Biomedical Research Excellence (COBRE) for Redox Biology and Cardiovascular Disease.
We participate in medical education at all levels. The Pathology Department is instrumental in teaching medical students the basic sciences and during their clinical clerkships, as well as providing resident and fellowship training. We also assist in the training of medical technology students in our School of Allied Health Professionals Physicians’ Assistant program, Pathologists’ Assistant program and graduate students in our School of Graduate Studies. We are very proud of our resident and fellow training as our residents score exceptionally well, scoring higher than the national mean on the Resident In-Service Exam (RISE). 100% of our residents pass the board exam for certification by The American Board of Pathology on their first attempt. Our residents also secure highly competitive positions in fellowship programs throughout the United States.
Our department has a long history of providing outstanding pathology patient services, both in anatomical pathology and clinical pathology locally, regionally, and nationally. Our clinical laboratories are all accredited by CLIA, CAP and AABB. Recently, our School and our department affiliated with the Ochsner Health System. The Ochsner Health System is an innovative and quality driven healthcare provider in the region. As a team, we will be able to continue the high value of care to our patients and expand our quality services to the region.
As the Chair, I feel very fortunate to have a team of highly skilled, talented, and dedicated pathologists in our department. This invaluable team of pathologists covers all facets of pathology, including general surgical pathology, cytology, forensic pathology, hematopathology, microbiology, transfusion medicine, chemistry, molecular pathology, and informatics. We have boarded subspecialists in cytopathology, hematopathology, neuropathology, forensic pathology, molecular pathology, transfusion medicine, dermatopathology and medical informatics. We also have fellowship-trained pathologists and pathologists with special expertise, all with vast experience in soft tissue and bone pathology, pulmonary pathology, GI-liver pathology, transplant pathology renal pathology, and GU pathology.
What determines excellence in a department of pathology? I believe excellence is rooted in a department's faculty. The faculty at LSU Health Shreveport's Department of Pathology are regarded nationally and internationally as experts in medical education, research, and clinical services. They have a dedication to and passion for timely and innovative research and the highest level of patient care. This faculty promotes an environment supportive of educating and mentoring our future healthcare workers, researchers, and leaders in our profession. Please feel welcome to read our website and visit us, where each day we continue to strive for excellence. If you have any questions or comment, please feel free to contact us.
Byron Crawford, MD
Phone: (318) 675-5860
Fax: (318) 675-8589
Residency / Fellowship
Phone: (318) 675-7822
Fax: (318) 675-7966
Phone: (318) 675-5869
Fax: (318) 675-6444
Phone: (318) 675-8475
Fax: (318) 675-7514
Phone: (318) 675-5861
Fax: (318) 675-8144
Patient Client Services
Phone: (318) 675-5918
Fax: (318) 675-4568
At LSU Health Shreveport, we offer a wide variety of consultative services in both Anatomic and Clinical Pathology. If you don’t find what you need on our website please contact us.
Pathology Central Receiving: (888) 252-3902
Our Anatomic Pathology Division and Clinical Pathology Division technical and administrative personnel are not only knowledgeable but highly experienced in their area of expertise and embrace a team approach to quality care, education, and research.
Many of our clinical faculty members are leaders in their fields and enjoy national and international reputations. They participate in key national committees and serve in leadership roles in major national and international medical societies. They are truly engaged in the advancement of medical knowledge. Their publication record is excellent and they actively involve trainees in their research projects.
Anatomic Pathology has a diverse list of specialties and over 25 full-time faculty members. Diagnostic consensus sign out conferences multiple times per week provide the framework for diagnostic excellence in the many subspecialty areas.
Hematology studies the blood and blood-forming tissues to evaluate presence of disease and assist in therapeutic interventions as clinically indicated. LSU Health Shreveport has highly qualified technical staff to assist you with any question in this area.
Molecular Pathology is the study of disease and chromosomal abnormalities at the molecular level to aid in diagnosis and therapeutic intervention of disease processes. The three areas of testing include genetics, hematopathology, and infectious disease.
Clinical Pathology has eight full time subspecialty trained and Board Certified Faculty. Oversight is provided for our Hematopathology, Wet Hematology, Coagulation, Flow Cytometry, Blood Bank, Apheresis, Routine and Special Chemistry and Point of Care, Lab Information, Microbiology, Virology, Parasitology, Cytogenetics, and Molecular Genetics Services.
Our combined research explores cell-matrix interactions, cell signaling, biochemical redox biology, and regulation of autophagy in chronic inflammation and cardiovascular remodeling.
JanOne Acquires Worldwide, Exclusive License for Promising Treatment of Peripheral Arterial Disease (PAD), TV1001SR, which was invented by LSU Health Shreveport professor and vice chancellor for research, Dr. Chris Kevil.
Rodney Shackelford, DO, PhD, Assistant Professor of Pathology, has been awarded a $40,000 grant from the A-T Children’s Project for his research project titled, “Pharmacologic Correction of the Cellular Sulfide Pool as a Treatment for Ataxia-Telangiectasia.”
LSU Health Shreveport researchers recently presented preliminary findings at the American Heart Association’s Basic Cardiovascular Sciences 2019 Scientific Sessions that use of the illegal stimulant methamphetamine causes build-up of tough protein fibers in heart muscle, which may help explain the development of enlarged hearts and heart failure in users.
The goal by Md. Shenuarin Bhuiyan, PhD, is to discover a novel lipid metabolism pathway regulated by Sigmar1 and identify a therapeutic target to prevent lipid abnormalities in obesity, expected to help reverse the impact of obesity on cardiovascular disease risk.